Strs Ohio Sells 46,646 Shares of Eli Lilly and Company $LLY

Strs Ohio trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 292,858 shares of the company’s stock after selling 46,646 shares during the period. Eli Lilly and Company comprises 0.8% of Strs Ohio’s holdings, making the stock its 15th largest position. Strs Ohio’s holdings in Eli Lilly and Company were worth $223,451,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new position in Eli Lilly and Company during the second quarter worth $8,827,714,000. Jennison Associates LLC increased its holdings in Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after buying an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Eli Lilly and Company by 2.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after acquiring an additional 103,119 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.8%

Shares of LLY opened at $1,087.63 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The firm has a market cap of $1.03 trillion, a price-to-earnings ratio of 53.21, a PEG ratio of 0.81 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The business’s fifty day moving average is $1,056.39 and its 200-day moving average is $878.04.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched a Phase 3b dosing study for retatrutide in obesity, advancing a leading obesity candidate toward optimized dosing and broader label/market potential. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Retatrutide trial data suggest potential knee osteoarthritis symptom benefit tied to weight loss — could expand clinical and commercial appeal beyond pure weight metrics. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: SURMOUNT?REAL UK (phase 4) will provide real?world tirzepatide data in obesity — useful for uptake, payer conversations and long?term market sizing. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: FDA granted Breakthrough Therapy designation to sofetabart (mipitecan) for certain platinum?resistant ovarian cancer patients — accelerates development path and raises long-term oncology upside. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Initiated a Phase 2 oral pain program for diabetic nerve pain — diversification of pipeline into high?unmet?need pain indications could add medium?term value. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Announced a Phase 1 PET tracer imaging study to broaden oncology imaging capabilities — early stage, strategic but long?timeline impact. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Neutral Sentiment: Confirmed Q4 2025 earnings date (Feb 4) — sets the calendar for next major catalyst and likely some pre?earnings positioning. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Market commentary pieces (buy/preview, breakout) and an explainer on why LLY is up today summarize investor enthusiasm and momentum ahead of results; useful but opinion?driven. Why Eli Lilly (LLY) stock is up today
• Negative Sentiment: Coverage notes Novo Nordisk’s new CEO is expected to intensify competition in obesity treatments — a reminder of pricing, market?share and reimbursement risks. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. UBS Group started coverage on shares of Eli Lilly and Company in a research note on Tuesday, January 6th. They set a “buy” rating and a $1,250.00 price objective on the stock. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, January 14th. Wolfe Research increased their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.